.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech plan to note on the Nasdaq under the symbol “BIOA,” depending on to files filed along with the Securities and Exchange Percentage. The firm has actually certainly not publicly shared an anticipated financial amount for the offering.The clinical-stage company boasts lead applicant azelaprag, a by mouth provided little particle slated to enter period 2 testing in combination along with semaglutide– offered by Novo Nordisk under brand Wegovy for weight reduction– in the very first half of upcoming year. Semaglutide is actually additionally offered as Ozempic and also Rybelsus through Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually created to blend well along with GLP-1 medicines, increasing fat burning while preserving muscle mass. The investigational drug was actually discovered to be well-tolerated one of 265 individuals all over 8 period 1 trials, according to BioAge.Earlier, BioAge achieved the support of Lilly to run a test blending azelaprag with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro as well as Zepbound for weight reduction. The companions are presently performing a period 2 test of azelaprag and also tirzepatide, along with topline results assumed in the 3rd quarter of 2025.The biotech is actually additionally intending an insulin sensitiveness proof-of-concept test determining azelaprag as a monotherapy in the very first fifty percent of following year to sustain potential evidence development.
On top of that, the firm considers to talk to the FDA for approval in the second one-half of 2025 to release human testing for an NLRP3 prevention targeting metabolic diseases as well as neuroinflammation.BioAge’s expected move to the public market complies with a mild uptick in planned biotech IPOs coming from Bicara Therapies and also Zenas Biopharma. Zooming out, the latest IPO landscape is a “mixed photo,” with premium providers still debuting on the general public markets, just in minimized amounts, depending on to PitchBook.